Johnson & Johnson (Johnson & Johnson) Change In Receivables : $-624 Mil (TTM As of Dec. 2023)

View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson Change In Receivables?

Johnson & Johnson's change in receivables for the quarter that ended in Dec. 2023 was $227 Mil. It means Johnson & Johnson's Accounts Receivable declined by $227 Mil from Sep. 2023 to Dec. 2023 .

Johnson & Johnson's change in receivables for the fiscal year that ended in Dec. 2023 was $-624 Mil. It means Johnson & Johnson's Accounts Receivable increased by $624 Mil from Dec. 2022 to Dec. 2023 .

Johnson & Johnson's Accounts Receivable for the quarter that ended in Dec. 2023 was $14,873 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Johnson & Johnson's Days Sales Outstanding for the three months ended in Dec. 2023 was 63.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Johnson & Johnson's liquidation value for the three months ended in Dec. 2023 was $-59,112 Mil.

Johnson & Johnson Change In Receivables Historical Data

The historical data trend for Johnson & Johnson's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Change In Receivables Chart

Johnson & Johnson Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-289.00

774.00

-2,402.00

-1,290.00

-624.00

Johnson & Johnson Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-54.00	-545.00	-252.00	227.00	-

Johnson & Johnson Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-624 Mil.

Johnson & Johnson (NYSE:JNJ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Johnson & Johnson's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	14873	/	21395	*	91
=	63.43

2. In Ben Graham's calculation of liquidation value, Johnson & Johnson's accounts receivable are only considered to be worth 75% of book value:

Johnson & Johnson's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	22927	-	98784	+	0.75 * 14873	+	0.5 * 11181
=	-59,112

Johnson & Johnson Change In Receivables Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (Johnson & Johnson) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Executives

Timothy Schmid	officer: EVP, WW Chair, MedTech	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait	officer: See Remarks	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo	officer: VP, Worldwide Human Resources	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel	officer: EVP, Chief GSC Officer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed	officer: EVP, Pharmaceuticals R&D	ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson	officer: EVP, Chief Information Officer	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk	officer: Exec VP, CFO	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy	officer: EVP, WW Chair, Medical Devices	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert	officer: EVP, WW Chair, Pharmaceuticals	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Robert J Decker	officer: Controller, CAO	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon	officer: Exec VP, WW Chair, Consumer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard	officer: Executive VP, General Counsel	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk	director	855 S. MINT STREET, CHARLOTTE NC 28202
Vanessa Broadhurst	officer: EVP, Global Corp Aff.	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933